The use of infliximab therapeutic drug monitoring in virtual biologics clinic for inflammatory bowel disease (IBD) leads to clinically durable results

被引：0
|
作者：
Sagar, R. [1 ]
Lenti, M. [1 ]
Clark, T. [1 ]
Rafferty, H. [1 ]
Gracie, D. [1 ]
Ford, A. [1 ]
O'Connor, A. [1 ]
Hamlin, J. [1 ]
Ahmad, T. [2 ]
Selinger, C. [1 ]
机构：
[1] St James Univ Hosp, Gastroenterol, Leeds, W Yorkshire, England
[2] Royal Devon & Exeter Fdn Trust, Gastroenterol, Exeter, Devon, England
来源：
JOURNAL OF CROHNS & COLITIS | 2018年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P737
引用
收藏
页码：S484 / S485
页数：3
相关论文
共 50 条
  • [31] Therapeutic drug monitoring of infliximab in inflammatory bowel disease patients in a teaching hospital setting: results of a prospective cohort study
    Warman, Andrea
    Straathof, Jan Willem A.
    Derijks, Luc J. J.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2015, 27 (03) : 242 - 248
  • [32] Usefulness of therapeutic drug monitoring of infliximab during the induction period in patients with inflammatory bowel disease
    Gil Candel, Mayte
    Gascon Canovas, Juan Jose
    Urbieta Sanz, Elena
    Gomez Espin, Rosa
    Nicolas de Prado, Isabel
    Iniesta Navalon, Carles
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2020, 112 (05) : 360 - 366
  • [33] Proactive Therapeutic Drug Monitoring in Pediatric Inflammatory Bowel Disease Patients Receiving Infliximab and Biosimilars
    Aktay, Atiye
    Odolil, Abel
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (12S): : S21 - S21
  • [34] Review article: a clinician's guide for therapeutic drug monitoring of infliximab in inflammatory bowel disease
    Khanna, R.
    Sattin, B. D.
    Afif, W.
    Benchimol, E. I.
    Bernard, E. -J.
    Bitton, A.
    Bressler, B.
    Fedorak, R. N.
    Ghosh, S.
    Greenberg, G. R.
    Marshall, J. K.
    Panaccione, R.
    Seidman, E. G.
    Silverberg, M. S.
    Steinhart, A. H.
    Sy, R.
    Van Assche, G.
    Walters, T. D.
    Sandborn, W. J.
    Feagan, B. G.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2013, 38 (05) : 447 - 459
  • [35] Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease-Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
    Little, Robert D.
    Ward, Mark G.
    Wright, Emily
    Jois, Asha J.
    Boussioutas, Alex
    Hold, Georgina L.
    Gibson, Peter R.
    Sparrow, Miles P.
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (20)
  • [36] Therapeutic drug monitoring in inflammatory bowel disease reduces unnecessary use of infliximab with substantial associated cost-savings
    Wu, Yang
    Lin, Brian
    Thilakanathan, Cynthuja
    Lehmann, Patritica
    Xuan, Wei
    Mohsen, Waled
    Toong, Catherine
    Williams, Astrid-Jane
    Ng, Watson
    Connor, Susan
    INTERNAL MEDICINE JOURNAL, 2021, 51 (05) : 739 - 745
  • [37] A role for therapeutic drug-monitoring during infliximab induction treatment in inflammatory bowel disease?
    Rasmussen, M.
    Brynskov, J.
    Ainsworth, M. A.
    Buhl, S.
    Bendtzen, K.
    Steenholdt, C.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S378 - S378
  • [38] Monitoring inflammatory Bowel disease activity in a virtual biologic clinic: The effects of proactive therapeutic drug monitoring on patient reported outcome measures
    Mc Gettigan, N.
    McNally, M.
    Deane, C.
    Keogh, A.
    Costello, R.
    Slattery, E.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S326 - S327
  • [39] VARIATIONS IN INTERPRETATION OF THERAPEUTIC DRUG MONITORING RESULTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
    Szeto, Winnie
    Moss, Alan C.
    Farraye, Francis
    GASTROENTEROLOGY, 2017, 152 (05) : S389 - S390
  • [40] Review article: determination of the therapeutic range for therapeutic drug monitoring of adalimumab and infliximab in patients with inflammatory bowel disease
    Gibson, David J.
    Ward, Mark G.
    Rentsch, Clarissa
    Friedman, Antony B.
    Taylor, Kirstin M.
    Sparrow, Miles P.
    Gibson, Peter R.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (06) : 612 - 628
12345